StockNews.AI
MIRA
StockNews.AI
3 hrs

MIRA Pharmaceuticals Closes Acquisition of SKNY Pharmaceuticals, Expands Pipeline with SKNY-1 for Obesity and Nicotine Addiction

1. MIRA completes acquisition of SKNY, gaining $5 million in marketable securities. 2. Financial position strengthened, supporting MIRA's programs like Ketamir-2 and MIRA-55.

M&A
-0.49%Current Return
VS
-0.17%S&P 500
$1.3309/30 07:36 AM EDTEvent Start
$1.323509/30 10:08 AM EDTLatest Updated
2m saved
Insight
Article

FAQ

Why Bullish?

The acquisition and capital infusion improve MIRA's financial health, reminiscent of past successful growth-driven acquisitions within biotech firms, which often lead to increased investor confidence and stock price appreciation.

How important is it?

With the $5 million infusion directly improving MIRA's operational capabilities, this announcement is likely to positively impact investor perception and stock market performance.

Why Short Term?

The immediate positive financial news and strengthened balance sheet can boost investor sentiment quickly, mirroring other companies that saw rapid price increases following similar announcements.

Related Companies

SKNYFBIOAXGT
Closing adds $5 million in marketable securities, strengthens financial position, and complements MIRA's advancing programs including Ketamir-2 and MIRA-55 MIAMI, FLORIDA / ACCESS Newswire / September 30, 2025 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) ("MIRA" or the "Company"), a clinical-stage pharmaceutical company focused on developing novel therapeutics for neurologic, neuropsychiatric, and metabolic disorders, today announced that it has completed its acquisition of SKNY Pharmaceuticals, Inc. ("SKNY"). As part of the transaction, SKNY fulfilled all closing obligations, contributing $5 million in marketable securities to MIRA, further strengthening the Company's balance sheet.

Related News